If you are not happy with the results below please do another search
Earlier this month, Neuralink said tiny wires implanted in the brain of its first patient had pulled out of position. Reuters reported last week, citing sources, the company knew from animal testing that the wires might retract.
H4B Chelsea President Violet Aldaia was recently elected the new board chair of the Coalition for Healthcare Communication (CHC). Med Ad News recently spoke with Aldaia to get a quick take on the issues she feels are most important for CHC to address this year.
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso.
In an oral decision, the European patent authority maintained the validity of Moderna’s patent ‘949 which describes and protects specific alterations to mRNA molecules designed to lower its immunogenicity, bypass the immune system and boost its translation in the body—as well as the potential uses of the modified mRNA.
According to key opinion leaders (KOLs) interviewed by GlobalData, the prevalence of HIV will reduce in the future, partly due to better treatment options, the availability of PrEP, and the development of prophylactic vaccines.
The facility, which will be the drugmaker’s first end-to-end antibody-drug conjugate production site, will be supported by the Singapore Economic Development Board.
Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk’s weight-loss drug Wegovy, researchers reported today.
Peregrine Market Access, a full-service consulting, communications, and commercialization partner for the life sciences industry, has promoted Alyson Popa to account director, Jennifer Sparano to senior vice president, director of corporate communications, and Stacey Thomas to vice president, director of project management.
According to GlobalData, more than 190 million people currently live with type 2 diabetes and/or obesity in seven major markets, and the numbers will be growing at an annual growth rate (AGR) of 1.35% and 0.57% for type 2 diabetes and obesity, respectively, in the next 10 years.
Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma companies. Will getting rid of management layers fix Bayer?